UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Intranasal challenge with B. pertussis leads to more severe disease manifestations in mice than aerosol challenge

PloS one, 2023-11, Vol.18 (11), p.e0286925-e0286925

2023

Volltextzugriff (PDF)

Teacher Support, Victimization, and Alcohol Use Among Sexual and Gender Minority Youth: Considering Ethnoracial Identity

Prevention science, 2021-07, Vol.22 (5), p.590-601

2021

Volltextzugriff (PDF)

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-10, Vol.24 (29), p.4721-4730

2006

Volltextzugriff (PDF)

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

BMC cancer, 2009-07, Vol.9 (1), p.263-263, Article 263

2009

Volltextzugriff (PDF)

RLIP76 and Cancer

Clinical cancer research, 2008-07, Vol.14 (14), p.4372-4377

2008

Volltextzugriff (PDF)

Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge

npj vaccines, 2022-03, Vol.7 (1), p.36-36, Article 36

2022

Volltextzugriff (PDF)

The Optical Stretcher: A Novel Laser Tool to Micromanipulate Cells

Biophysical journal, 2001-08, Vol.81 (2), p.767-784

2001

Volltextzugriff (PDF)

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

Cancer gene therapy, 2003-10, Vol.10 (10), p.737-744

2003

Volltextzugriff (PDF)

TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors

Journal of clinical oncology, 2004-02, Vol.22 (4), p.592-601

2004

Volltextzugriff (PDF)

Intratumoral Injection of INGN 241, a Nonreplicating Adenovector Expressing the Melanoma-Differentiation Associated Gene-7 (mda-7/IL24): Biologic Outcome in Advanced Cancer Patients

Molecular therapy, 2005-01, Vol.11 (1), p.160-172

2005

Volltextzugriff (PDF)

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-09, Vol.26 (27), p.4418-4425

2008

Volltextzugriff (PDF)

Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer

Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.875-890

2011

Volltextzugriff (PDF)

A Phase I trial of h‐ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma

Cancer, 2001-09, Vol.92 (5), p.1265-1271

2001

Volltextzugriff (PDF)

Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

Clinical cancer research, 2005-05, Vol.11 (10), p.3846-3853

2005

Volltextzugriff (PDF)

Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer

Molecular therapy, 2006-06, Vol.13 (6), p.1185-1191

2006

Volltextzugriff (PDF)

Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study

Molecular therapy, 2005-01, Vol.11 (1), p.149-159

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-11, Vol.11 (21), p.7825-7833

2005

Volltextzugriff (PDF)

Actin-Binding Protein Requirement for Cortical Stability and Efficient Locomotion

Science (American Association for the Advancement of Science), 1992-01, Vol.255 (5042), p.325-327

1992

Volltextzugriff (PDF)

Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions

Anti-cancer drugs, 2007-03, Vol.18 (3), p.283-289

2007

Volltextzugriff (PDF)

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS4192-TPS4192

2024

Volltextzugriff (PDF)

Abstract 4533: Serum protein changes in patients with desmoid tumors responsive to the TBL1 inhibitor, tegavivint

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4533-4533

2023

Volltextzugriff (PDF)

Cell Permeant Polyphosphoinositide-binding Peptides That Block Cell Motility and Actin Assembly

The Journal of biological chemistry, 2001-11, Vol.276 (46), p.43390-43399

2001

Volltextzugriff (PDF)

A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer

Clinical cancer research, 2000-05, Vol.6 (5), p.1626

2000

Volltextzugriff (PDF)

Actin Polymerization and Intracellular Solvent Flow in Cell Surface Blebbing

The Journal of cell biology, 1995-06, Vol.129 (6), p.1589-1599

Cunningham, C. Casey

1995

Volltextzugriff (PDF)

Immunization with an mRNA DTP vaccine protects against pertussis in rats

Infection and immunity, 2024-08, Vol.92 (8), p.e0052023

2024

Volltextzugriff (PDF)

1 – 25 von 352

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(274)
Mit Volltextzugriff
(316)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(352)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Intranasal challenge with B. pertussis leads to more severe disease manifestations in mice than aerosol challenge

Teacher Support, Victimization, and Alcohol Use Among Sexual and Gender Minority Youth: Considering Ethnoracial Identity

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

RLIP76 and Cancer

Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge

The Optical Stretcher: A Novel Laser Tool to Micromanipulate Cells

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors

Intratumoral Injection of INGN 241, a Nonreplicating Adenovector Expressing the Melanoma-Differentiation Associated Gene-7 (mda-7/IL24): Biologic Outcome in Advanced Cancer Patients

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer

A Phase I trial of h‐ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma

Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer

Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Actin-Binding Protein Requirement for Cortical Stability and Efficient Locomotion

Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations

Abstract 4533: Serum protein changes in patients with desmoid tumors responsive to the TBL1 inhibitor, tegavivint

Cell Permeant Polyphosphoinositide-binding Peptides That Block Cell Motility and Actin Assembly

A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer

Actin Polymerization and Intracellular Solvent Flow in Cell Surface Blebbing

Immunization with an mRNA DTP vaccine protects against pertussis in rats

Suchergebnisse filtern